

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
PZ0277

SERIAL NO.  
To Be  
Assigned **B**

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT  
Klaus Kopka

FILING DATE  
Herewith

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	3,952,971	04-1976	Grunberg, et.al.			
	4,124,760	11-1978	Green, et.al.			

FOREIGN PATENT DOCUMENTS

Documents not provided./LHS/							TRANSLATION	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS		YES	NO
	0293971	12-1988	EP					
	99/60018	11-1999	WO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Grams, Frank, et.al. "Pyrimidine-2,4,6-triones: A new effective and selective class of matrix metalloproteinase inhibitors" Biological Chemistry, vol. 382, no. 8, August 2001, pages 1277-1285
	Foley, Louise H., et.al., « Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors" Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 8, 23, April 2001 pages 969-972
	Grigsby RA, et.al., "New Brain Imaging Agents Selenium-75 labeled and Tellurium-123M Labeled Barbiturates" Journal of Nuclear Medicine, vol. 22, no. 6, 1981 pages P12-P13 (28 <sup>th</sup> Annual Meeting of the Society of Nuclear Medicine, Las Vegas, Nev., USA June 16-19, 1981
	Inorganic Chemistry, 1983, Vol. 22(24), pages 3562-3567, see page 3562 (2 <sup>nd</sup> paragraph to last paragraph: metal complexing barbituric acid 5-oxime "H <sub>2</sub> vi", <sup>13</sup> C variant & Na salts thereof) and page 3563 (3 <sup>rd</sup> - 6 <sup>th</sup> paragraphs: 5- <sup>15</sup> N labelled barbituric acid 5-oximes)
	Journal of Pharmaceutical Sciences, 1984, Vol. 73(3), PAGES 3394-3396, see especially references to

EXAMINER /Leah Schlientz/

DATE CONSIDERED

08/06/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/

10/530836

Sheet 2 of 2

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. PZ0277	SERIAL NO. To Be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Klaus Kopka	
		FILING DATE Herewith	GROUP To Be Assigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	radiolabelling on page 394 (paragraph bridging LH & RH columns) and in the paragraph bridging pages 395 & 396
	Journal of Organometallic Chemistry, 1983, Vol. 259(2), pages 171-181, see pages 171 (last sentence of summary) & 180 (penultimate paragraph)
	International Preliminary Examination Report for PCT/GB03/04351 dated 01/26/2005
	International Search Report for PCT/GB03/03451 dated 03/19/2004
	GB Search report for 0223249.4 dated 12 March 2003

/Leah Schlientz/

EXAMINER

DATE CONSIDERED 08/06/2009

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LS/